Who Prioritizes Innovation? R&D Spending Compared for BioMarin Pharmaceutical Inc. and Axsome Therapeutics, Inc.

Comparing R&D Priorities: BioMarin vs. Axsome

__timestampAxsome Therapeutics, Inc.BioMarin Pharmaceutical Inc.
Wednesday, January 1, 20144279200461543000
Thursday, January 1, 20156776987634806000
Friday, January 1, 201621199860661905000
Sunday, January 1, 201719957616610753000
Monday, January 1, 201823495055696328000
Tuesday, January 1, 201953647067715007000
Wednesday, January 1, 202070244579628116000
Friday, January 1, 202158060725628793000
Saturday, January 1, 202257947447649606000
Sunday, January 1, 202397944000746773000
Monday, January 1, 2024187077000747184000
Loading chart...

Unleashing insights

Innovation in Pharmaceuticals: A Tale of Two Companies

In the competitive world of pharmaceuticals, innovation is key to staying ahead. BioMarin Pharmaceutical Inc. and Axsome Therapeutics, Inc. exemplify this drive, albeit at different scales. Over the past decade, BioMarin has consistently invested heavily in research and development, with their R&D spending peaking at approximately $747 million in 2023. This represents a steady increase of about 62% from 2014. In contrast, Axsome Therapeutics, while operating on a smaller scale, has shown a remarkable growth trajectory. Their R&D expenses surged by over 2,000% from 2014 to 2023, reaching nearly $98 million. This stark difference highlights BioMarin's established presence and Axsome's aggressive push to innovate and expand. As the pharmaceutical landscape evolves, these investments underscore the critical role of R&D in driving future breakthroughs and maintaining competitive advantage.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025